Search

Your search keyword '"Petrini, Iacopo"' showing total 335 results

Search Constraints

Start Over You searched for: Author "Petrini, Iacopo" Remove constraint Author: "Petrini, Iacopo"
335 results on '"Petrini, Iacopo"'

Search Results

3. Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression

6. STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines

9. Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation

12. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities

18. Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management.

19. Molecular and Functional Key Features and Oncogenic Drivers in Thymic Carcinomas.

20. Somatic mutations of thymic epithelial tumors with myasthenia gravis

24. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer

29. Supplementary Figures 1-3, Tables 1-6 from Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer

31. Data from MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non–Small Cell Lung Carcinoma

32. Supplementary Figure 1 from MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non–Small Cell Lung Carcinoma

33. Supplementary Tables 1-9 from MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non–Small Cell Lung Carcinoma

34. Supplementary Appendix 1 from MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non–Small Cell Lung Carcinoma

37. Nanoscale engagement of immune checkpoint inhibitor PD-L1 in membrane lipid rafts

39. Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations

47. Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives

48. Additional file 3 of Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients

49. Additional file 1 of Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients

50. Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation

Catalog

Books, media, physical & digital resources